Theravance Biopharma reported second quarter 2026 financial results, showing progress on its pending acquisition by Zymeworks expected to close in the second half of 2026 for $17.00 per share in cash. YUPELRI collaboration revenue increased 11% year-over-year to $20.7 million, driven by continued net sales growth. The company's organizational restructuring delivered a 35% reduction in operating expenses year-over-year, excluding restructuring and transaction costs. TRELEGY net sales reached approximately $1.0 billion in Q2 2026, reported by GSK. The company expressed high confidence in achieving a $100 million 2026 milestone payment. Theravance Biopharma ended the quarter with a cash balance of $388 million and no debt. The company reported a net loss of $5.9 million for the quarter, compared to net income of $54.8 million in Q2 2025.

Zymeworks to report second quarter 2026 financial results on August 6, 2026. VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) - Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its second quarter 2026 financial results after market close on August 6, 2026. In light of the previously announced proposed acquisition of Theravance Biopharma, Zymeworks has elected not to host a second quarter earnings conference call after release of its financial results. We look forward to providing an update following the expected closing of the proposed acquisition of Theravance Biopharma, sharing greater visibility into the combined business and its strategic priorities. About Zymeworks Inc. Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease. Zymeworks' asset and royalty aggregation strategy focuses on optimizing positive future cash flows from an emerging portfolio of licensed products such as Ziihera(R)(zanidatamab-hrii) and other licensed products and product candidates, such as pasritamig. In addition, Zymeworks is building a portfolio of healthcare assets that can generate strong cash flows, while supporting the development of innovative medicines. Zymeworks engineered and developed Ziihera, a HER2-targeted bispecific antibody using Zymeworks' proprietary Azymetric(TM) technology and has entered into separate agreements with BeOne Medicines Ltd. (formerly BeiGene, Ltd.) and Jazz Pharmaceuticals Ireland Limited granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zymeworks is rapidly advancing a robust pipeline of product candidates, leveraging its expertise in both antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Investor Inquiries: Shrinal Inamdar Vice President, Investor Relations (604) 678-1388 [email protected] Media Inquiries: Diana Papove Vice President, Corporate Communications (604) 678-1388 [email protected] Company Profile Zymeworks Inc. Industry: Pharmaceuticals & Biotechnology Website: https://www.zymeworks.com/ Recommended reading.